ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC lifted its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 2.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 5,381,985 shares of the biotechnology company’s stock after purchasing an additional 137,989 shares during the quarter. Geode Capital Management LLC owned about 2.31% of ADMA Biologics worth $107,606,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Quest Partners LLC acquired a new stake in shares of ADMA Biologics in the 2nd quarter worth $29,000. Hollencrest Capital Management purchased a new stake in shares of ADMA Biologics in the third quarter valued at about $30,000. Larson Financial Group LLC acquired a new stake in ADMA Biologics during the third quarter worth about $31,000. National Bank of Canada FI purchased a new position in ADMA Biologics during the third quarter worth about $35,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in ADMA Biologics in the 3rd quarter valued at about $62,000. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Stock Down 5.0 %

ADMA Biologics stock opened at $17.70 on Thursday. The company has a market capitalization of $4.18 billion, a PE ratio of 63.21 and a beta of 0.70. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. ADMA Biologics, Inc. has a fifty-two week low of $4.06 and a fifty-two week high of $23.64. The firm has a 50 day moving average price of $18.90 and a 200 day moving average price of $16.24.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The business had revenue of $119.84 million during the quarter, compared to analysts’ expectations of $107.25 million. During the same period in the previous year, the firm posted $0.01 earnings per share. Research analysts expect that ADMA Biologics, Inc. will post 0.52 earnings per share for the current year.

Insider Transactions at ADMA Biologics

In related news, CFO Brad L. Tade sold 15,000 shares of ADMA Biologics stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total value of $317,250.00. Following the completion of the transaction, the chief financial officer now owns 199,433 shares in the company, valued at approximately $4,218,007.95. The trade was a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 3.70% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $20.00 price target on shares of ADMA Biologics in a research report on Friday, September 20th. Raymond James upped their price target on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research note on Friday, November 8th. Finally, HC Wainwright raised their price objective on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, November 8th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.